Barclays maintained a Sell rating on Puma Biotechnology (PBYI), noting that Trump-era tariffs and onshoring trends benefit AI stocks.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays maintained a Sell rating on Puma Biotechnology (PBYI), noting that Trump-era tariffs and onshoring trends benefit AI stocks.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Barclays
British bank
-
Puma Biotechnology (United States)
company in Los Angeles, United States
Nothing else this week.
Related events
- Aflac's profits are driven by operations in Japan, while AI stocks are benefiting from Trump-era tariffs.
- Market indices reflect company gains, while high-level talks proceed and Meta leverages AI agent successes.
- AEI suggests future active engagement as Trump's tariff hook leads to fragmentation and a post-Trump US search for global influence.
Coverage
Newest first; wire copies grouped- Insider MonkeyBarclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the top most undervalued biotech stocks to buy now. In a report released on